Skip to main content
Close

Centre for the Southern Interior


If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

 

Tumour Group / SiteTrial TitleOpening Date
Breast



Prospective study to evaluate the feasibility of partial breast irradiation utilizing permanent breast seed implants in BC. (PBSI)May
2012
A feasibility Study of Accelerated Partial Breast Irradiation with High Dose Rate Interstitial , Multi-Catheter Brachytherapy for Women with Early Stage Breast Cancer. (HDR)March 2013
Central Nervous System (CNS)
A phase II/III trial of Neoadjuvant Folfox, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients cancer patients undergoing low anterior resection with total mesorectal excision.
(NCIC CRC.7) 
April
2014
GU - Bladder
GU- ProstateImproving QOL after optimal RT for intermediate & high risk prostate ca: HDR vs. LDR Brachytherapy Boost.
(QOL study)
December
2013
GU - Renal A Phase III, multicenter, randomized Placebo-Controlled, Double-blind study of Atezolizumab (Anti-PD-L1 Antibody)
as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy.
(Roche W039210) 

March
2018

GU - Multi 
GyneA Randomized Placebo Controlled Phase ll trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD1775 (MK1775) PO in Women with Recurrent Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers. (PHL-093)
September
2015
Lung
A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in
Patients with Metastatic Non-Small Cell Lung Cancer.
(MERCK ECHO)
March
2018


A phase II study of Pembrolizumab in patients with advanced Malignant Pleural Mesothelioma (MPM). To evaluate whether pembrolizumab, alone or together with standard chemotherapy improves progression free survival in MPM.
(IND227)
February
2017
Lymphoma

Multiple Myeloma  
Melanoma

Multi-site
Supportive / Palliative Care
 

SOURCE: Centre for the Southern Interior ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2018 Provincial Health Services Authority